- THYROID HORMONE RECEPTOR AGONISTS
-
Provided herein are novel thyroid hormone receptor (TR) agonists, e. g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.
- -
-
-
- THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF
-
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
- -
-
-
- COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
The invention relates to a compound of Formula (I) or (IA) compositions comprising compounds of Formula (I) or (IA), and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula (I) or (IA) to a patient in need thereof:
- -
-
-
- NOVEL FLUORESCENT DYES AND USES THEREOF
-
The present invention provides fluorescent dyes that are based on firefly luciferin structure. These dyes are optimally excited at shorter wavelengths and have Stokes shift of at least 50 nm. The fluorescent dyes of the invention are useful for preparation of dye-conjugates, which can be used in detection of an analyte in a sample.
- -
-
Page/Page column 32-33
(2011/02/24)
-
- INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION
-
The present invention relates to a compound of formula: (I), or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 62-63
(2010/02/11)
-
- Identification of hydroxylated PCB metabolites and other phenolic halogenated pollutants in human blood plasma
-
A growing number of studies have reported phenolic halogenated compounds (PHCs) that are retained in the blood of humans and wildlife. These PHCs may be industrial chemicals; metabolites thereof, as in the case with polychlorobiphenylols (OH-PCBs); or of natural origin. The present study was aimed to identify hitherto unknown PHCs in human plasma with chemical structures that are consistent to PHCs known to possess endocrine-disrupting activity. For this purpose, samples of blood plasma from 10 randomly selected male blood donors from Sweden were pooled and analyzed by GC/ECD and GC/MS. Brominated, bromochlorinated, and chlorinated methyl derivatives of phenols and OH-PCBs were synthesized to be used as authentic reference standards. More than 100 PHCs were indicated in the plasma, and among those a total of 9 monocyclic brominated or chlorinated phenol-, guaiacol-, and/or catechol-type compounds were identified as their methylated derivatives. The two major compounds were 2,4,6-tribromophenol and pentachlorophenol. Thirty-eight OH-PCB congeners were structurally identified on two GC columns of different polarity. The origin of the OH-PCB metabolites in the context of their parent PCB congeners are suggested. Other PHCs identified in the male plasma were Triclosan (5-chloro-2-[2,4-dichlorophenoxy] phenol), a common bactericide; 4-hydroxy-heptachlorostyrene, a metabolite of octachlorostyrene; and 3,5-dibromo-2-(2,4-dibromophenoxy)phenol, a natural compound and a potential metabolite of polybrominated diphenyl ethers.
- Hovander,Malmberg,Athanasiadou,Athanassiadis,Rahm,Bergman,Wehler, E. Klasson
-
p. 105 - 117
(2007/10/03)
-
- Pyridazinedione compounds useful in treating neurological disorders
-
The present invention relates to pyridazino[4,5-b]quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]quinolines as active ingredient, and methods for the treatment of neurological disorders.
- -
-
-